Journal Article Ahead of print
PubMed: 42227178 DOI: 10.1093/trstmh/trag067
Dolutegravir-lamivudine dual therapy in subtype C HIV: implications for India and beyond.
Trans R Soc Trop Med Hyg
Authors: Praveen Kumar Tirlangi, Carl Boodman, Bayode R Adegbite, Martin P Grobusch, Nitin Gupta
Affiliations
- Department of Infectious Disease, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, India.
- Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium.
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Public Health - Global Health, Amsterdam Infection & Immunity, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
- Centre de Recherches Médicales en Lambaréné (CERMEL), B.P. 242, Lambaréné, Gabon.
- Masanga Medical Research Unit (MMRU), Masanga, Sierra Leone.
- Institut für Tropenmedizin und Deutsches Zentrum für Infektiologie (DZIF), Universität Tübingen, Tübingen, Germany.
- Institute of Molecular Medicine and Infectious Diseases, University of Cape Town, Cape Town, South Africa.
- Department of Infectious Disease, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, India. Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium. Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Public Health - Global Health, Amsterdam Infection & Immunity, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
MeSH
Hygiene, Lamivudine, Hiv, Therapeutics, Dolutegravir